A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Neuropsychiatric symptoms (NPS) in Alzheimer's Disease (AD) are associated with negative outcomes for patients and their care partners. Agitation is a common and distressing NPS, without safe and effective treatments. Nonpharmacological interventions are first line treatment, but not effective or appropriate for every patient. Current pharmacological treatments of agitation in AD include off-label use of antipsychotics, sedative/hypnotics, anxiolytics, mood-stabilizing anticonvulsants, acetylcholinesterase inhibitors, NMDA receptor antagonists, and antidepressants. Despite prevalent use, efficacy and safety concerns remain. AREAS COVERED: Better understanding of neurobiological mechanisms of agitation have fueled recent clinical trials. This article is an update to our 2017 review. Comprehensive search of ClinicalTrials.gov was completed from January 2017 to February 2023 using the search terms "Alzheimer's Disease" and "Agitation". Subsequent scoping review was completed in PubMed and Google Scholar. Several agents were identified, including: brexpiprazole, cannabinoids, dexmedetomidine, dextromethorphan, escitalopram, masupirdine, and prazosin. EXPERT OPINION: Clinical trials utilize both novel and repurposed agents for agitation in AD. With increasing understanding of the neurobiological mechanisms that fuel development of agitation in AD, use of enahanced trial design and conduct, advanced statistical approaches, and accelerated pathways for regulatory approval, we advance closer to safe and efficacious treatment options for agitation in AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2023, brexpiprazole was approved by the FDA for AD-related agitation, showing moderate efficacy at 2 mg/d.37,38”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [37]
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
Weerink, M. A. S., Struys, M. M. R. F., Hannivoort, L. N., Barends, C. R. M., Absalom, A. R., & Colin, P. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0507-7 · Cited by 1,208
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Zhao, Q.-F., Tan, L., Wang, H.-F., Jiang, T., Tan, M.-S., Tan, L., Xu, W., Li, J.-Q., Wang, J., Lai, T.-J., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.069 · Cited by 916
Schneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Raskind, M. A., Peskind, E. R., Kanter, E. D., Petrie, E. C., Radant, A., Thompson, C. E., Dobie, D. J., Hoff, D., Rein, R. J., Straits-Tröster, K., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.371 · Cited by 607
Kales, H. C., Gitlin, L. N., Lyketsos, C. G., & Dementia, T. D. E. P. O. T. A. A. M. O. T. N. S. O. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12730 · Cited by 575
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572
Self-citationNonpharmacologic Management of Behavioral Symptoms in Dementia
Gitlin, L. N., Kales, H. C., & Lyketsos, C. G. (2012) · JAMA · doi:10.1001/jama.2012.36918 · Cited by 495
Research works printed but not linked: 15
- Patterson C., 2018, An analysis of prevalence, incidence, cost and trends.
- Otsuka Pharmaceutical Co. Otsuka Pharmaceutical and Lundbeck announce positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole [Press Release]. Otsuka Pharmaceutical Co., H. Lundbeck A/S; 2022 [updated June 27]. Available from: https://www.otsuka.co.jp/en/company/newsreleases/2022/20220627_1.html
- Lundbeck A/S H. Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole at the 2022 Alzheimer’s Association International Conference [Press Release]. 2022 [updated August 4]. Available from: https://newsroom.lundbeckus.com/news-release/2022/otsuka-pharmaceutical-and-lundbeck-present-positive-results
- Lundbeck A/S H. Otsuka Pharmaceutical and Lundbeck Present Positive Data from Multiple Phase 3 Studies Showing Brexpiprazole Significantly Improved Symptoms of Agitation in Patients with Alzheimer’s Dementia at the 2022 Clinical Trials for Alzheimer’s Disease Congress [Press Release]. 2022 [updated December 2]. Available from: https://newsroom.lundbeckus.com/news-release/2022/otsuka-pharmaceutical-and-lundbeck-present-positive-data-from-mu
- Otsuka Pharmaceutical Co. Otsuka and Lundbeck Announce Decision to Continue Phase III Clinical Trial Evaluating Brexpiprazole for Treatment of Agitation in Patients with Alzheimer’s-type Dementia [Press Release]. 2021 [updated April 13]. Available from: https://www.otsuka-us.com/node/1286
- Otsuka Pharmaceutical Co. Otsuka and Lundbeck announce FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia [Press Release]. Otsuka Pharmaceutical Co., Ltd., Lundbeck A/S; 2023 [updated January 7; cited 2023 February 24]. Available from: https://www.otsuka-us.com/news/otsuka-and-lundbeck-announce-fda-acceptance-and-priority-review-snda-brexpiprazole-treatment
- Sunnybrook Health Sciences Centre AsDDF, Weston Brain Institute, 2021, Nabilone for Agitation Blinded Intervention Trial
- BioXcel Therapeutics. BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia [Press Release]. 2021 [updated March 15]. Available from: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-receives-fda-breakthrough-therapy
- BioXcel Therapeutics. BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease [Press Release]. 2021 [updated January 5]. Available from: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-bxcl501-met-primary-and-all
- Axsome Therapeutics. Axsome Therapeutics receives fda breakthrough therapy designation for axs-05 for the treatment of alzheimer’s disease agitation [Press Release]. 2020 [updated June 26]. Available from: https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-receives-fda-breakthrough-therapy-0
- Avanir Pharmaceuticals. Avanir Pharmaceuticals, Inc. Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer’s Dementia [Press Release]. 2019 [updated March 24]. Available from: https://www.avanir.com/press/avanir-pharmaceuticals-inc-reports-phase-3-data-evaluating-investigational-avp-786-treatment
- Axsome Therapeutics. Axsome Therapeutics announces axs-05 achieves primary endpoint in the accord phase 3 trial in alzheimer’s disease agitation [Press Release]. 2022 [updated November 28]. Available from: https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-3
- 10.1176/jnp.16.3.261 · doi:10.1176/jnp.16.3.261 · Paper page
- Alzheimer’s Disease Cooperative Study NIoA, 2018, Prazosin for Agitation in Alzheimer’s Disease
- Peskind ER, 15th Conference Clinical Trials Alzheimer’s Disease (CTAD)
Cited by
A 2025 update on treatment strategies for the Alzheimer’s disease spectrum
Wu, C.-K., & Fuh, J.-L. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001252 · Cited by 77
Vediappan, P., Arumugam, M., & Natarajan, R. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099282836231212064925 · Cited by 34
O USO DAS PROTEÍNAS ΒETA-AMILOIDE E TAU COMO NOVA ABORDAGEM TERAPÊUTICA NA DOENÇA DO ALZHEIMER
Pimentel, A. P. A., Rosas, B. D. P. S., Parente, C. T. C., & Rezende, G. D. O. (2024) · Revista Contemporânea · doi:10.56083/rcv4n10-192 · Cited by 24
Timler, A., Bulsara, C., Bulsara, M. K., Vickery, A. W., Smith, J., & Codde, J. (2020) · Trials · doi:10.1186/s13063-020-4085-x · Cited by 29
Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer’s Disease
Imbimbo, C., Ramusino, M. C., Leone, S., Mazzacane, F., Franco, V. D., Gatti, A., Perini, G., & Costa, A. C. (2024) · CNS Drugs · doi:10.1007/s40263-024-01133-9 · Cited by 23
Metadata
- Authors
- Lee, D., Clark, E. D., Antonsdottir, I. M., & Porsteinsson, A. P.
- Affiliations
- University of Rochester Medicine (US)
- Johns Hopkins University (US)
- Corresponding author
- Porsteinsson, Anton P.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2023-03-28
- Volume
- 24
- Issue
- 6
- Pages
- 691-703
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W4360602811
- Cited by
- 28
- References
- 55
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 10 · 2023: 1
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, agitation, neuropsychiatric symptoms, pharmacotherapy, non-pharmacological treatment, antipsychotic drugs, sedative-hypnotic drugs, anxiolytics, acetylcholinesterase inhibitors, NMDA receptor antagonists, antidepressants, brexpiprazole, cannabinoids, dexmedetomidine, dextromethorphan, escitalopram, prazosin, drug repurposing, neurobiological mechanisms, clinical trials
- MeSH terms
- Acetylcholinesterase, Alzheimer Disease, Antidepressive Agents, Humans, Psychomotor Agitation, Antipsychotic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease. https://app.cochat.ai/papers/10.1080/14656566.2023.2195539
- The paper
- Lee, D., Clark, E. D., Antonsdottir, I. M., & Porsteinsson, A. P. (2023). A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2023.2195539
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.